Ethosuximide to Treat IBS

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Abdominal pain remains the most deleterious symptom for patients with irritable bowel syndrome (IBS) and is causing a significant alteration of their quality of life. The visceral hypersensitivity seems to be one of the key mechanisms that could explain the abdominal pain in these patients. Current treatments, mainly symptomatic, are of limited effectiveness, especially in terms of relief of abdominal pain. The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Collaborators: SFETD (Socièté Française d'Etude et de Traitement de la Douleur); SFETD (Socièté Française d’Etude et de Traitement de la Douleur)
• Treatments: Ethosuximide

Criteria

Inclusion Criteria:

• Age ≥ 18 years,

• Man,

• Women, Negative pregnancy test and effective contraception,

• IBS defined by the Rome criteria IV

• During the previous seven days the inclusion visit, average NRS pain ≥ 4,

• IBS Treatment stable for 1 month

• Patients affiliated to the French Social Security,

• Patients with the informed consent were obtained.

Exclusion Criteria:

• Breastfeeding

• Diabetic patients

• Known renal or hepatic impairment,

• Significant liver function abnormalities (transaminases> 3N, cholestasis) and renal (MDRD <60 ml / min)

• Addiction to alcohol and / or drugs,

• AEDs taken (epilepsy or chronic pain)

• chronic pain of greater intensity than that related to IBS,

• Allergy succinimides (ethosuximide, methsuximide, phensuximide)

• History or current severe depression (hospitalization, long-term antidepressant treatment)

• Psychotic disorders,

• Patients exclusion period, or total exceeded authorized allowances

• Patients undergoing a measure of legal protection (trusteeship, guardianship ...).